CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Bristol Myers Squibb is acquiring 2seventy bio ... Graybosch noted that 2seventy CEO Chip Baird stated at an investor conference last week that his company’s move toward profitability makes ...

Leung will be succeeded by Cari Gallman, the company's executive vice president of corporate affairs, Bristol Myers CEO Chris Boerner ... in shaping Bristol Myers Squibb into the innovative ...

At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

In a regulatory filing on Friday night, Bristol Myers (BMY) disclosed that its CEO Christopher Boerner bought ... Bristol-Myers Squibb NewsMORE Related Stocks Indices Commodities Currencies ...